Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Jack Eckerd (up 4-3/4to 30-5/8) and Rorer (up 3-1/2 to 37), moving on merger speculation, were the leaders on the "F-D-C" Index during the otherwise sluggish week ended Aug. 23. Overall, declines kept pace with advancing issues as 22 gained, 21 lost ground and 8 stocks remained unchanged. The Composite showed no change for the week, while the Dow inched up .4% to 1318.32. Rorer's 3-1/2 point move occurred on Aug. 22-23 when the "Street" rumor mill once again began to see Pfizer at Rorer's door. Rumors tying Rorer with Pfizer surfaced last month based on reports of a speech by Rorer's new chief exec Robert Cawthorn to the firm's European managers that supposedly gave some indication of an impending merger. Also feeding the rumors of a Rorer/Pfizer wedding is Cawthorn's former association with Pfizer. Before assuming the top operating spot at Biogen, Cawthorn had held the position of exec VP at Pfizer-Europe. Eckerd's move stemmed from an Aug. 21 announcement by the drug chain that it was willing to discuss a merger with interested parties and that it already has had "preliminary discussions" with several firms. Also showing gains for the week were Merck (up 2-1/4 to 117) and Abbott (up 2-1/8 to 10) among the Diversifieds. The several stocks showing price weakness during the week included Bolar (down 4-1/4 to 13-1/8) and Upjohn (down 3 to 108-3/8). FDA has asked Bolar not to market over 60 unapproved reformulated products. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts